Literature DB >> 25661407

High lipoprotein(a) concentrations are associated with impaired endothelial function in children.

Jouni Lapinleimu1, Olli T Raitakari2, Helena Lapinleimu3, Katja Pahkala4, Tapani Rönnemaa5, Olli G Simell6, Jorma S A Viikari5.   

Abstract

OBJECTIVE: To examine the association between familial high lipoprotein(a), or Lp(a), concentrations and endothelial function in children participating in the Special Turku Coronary Risk Factor Intervention Project study. STUDY
DESIGN: Seven-month-old children (n = 1062) with their families were randomized to a risk intervention group or to a control group. The intervention group received individualized dietary counseling to reduce the total cholesterol concentration. Children's Lp(a) and lipid values were measured repeatedly. At age 11 years, children were recruited to an ultrasound study of the flow-mediated dilation (FMD) of the brachial artery. The association between relative peak FMD and Lp(a) concentration was examined in 198 control and 193 intervention group children by linear regression analyses adjusted for sex, total cholesterol concentration, and basal artery diameter. The analyses were made in both the control and intervention groups and in the familial risk children who had a parent with Lp(a) concentration greater than 250 mg/l.
RESULTS: Lp(a) concentrations were similar at age 11 years in the intervention and control groups. In all control children, FMD (%) associated inversely with Lp(a) concentration: (β [%/1000 mg/L] = -3.74, 95% CI [-6.43, -1.45]; P = .007) and in 68 familial risk children (β = -4.92, 95% CI [-8.18, -1.66]; P = .0037). In the intervention group the associations were lacking (P > .5), and FMD in the children with high Lp(a) concentrations (>500 mg/L, n = 12) had no attenuation (P = .027).
CONCLUSIONS: Familial high Lp(a) concentration is associated with attenuated endothelial function. This association may be mitigated by an early lifestyle intervention. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00223600.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25661407     DOI: 10.1016/j.jpeds.2014.12.051

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  4 in total

1.  Lipoprotein (a): Examination of Cardiovascular Risk in a Pediatric Referral Population.

Authors:  Omar Qayum; Noor Alshami; Chizitam F Ibezim; Kimberly J Reid; Janelle R Noel-MacDonnell; Geetha Raghuveer
Journal:  Pediatr Cardiol       Date:  2018-06-13       Impact factor: 1.655

2.  Similar Myocardial Perfusion and Vascular Stiffness in Children and Adolescents with High Lipoprotein (a) Levels, in Comparison with Healthy Controls.

Authors:  Kyriaki Papadopoulou-Legbelou; Areti Triantafyllou; Olga Vampertzi; Nikolaos Koletsos; Stella Douma; Efimia Papadopoulou-Alataki
Journal:  Pulse (Basel)       Date:  2021-09-10

3.  LPA Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels.

Authors:  Andreja Rehberger Likozar; Aleš Blinc; Katarina Trebušak Podkrajšek; Miran Šebeštjen
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-13

4.  Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents.

Authors:  Jason G van Genderen; Malon Van den Hof; Claudia G de Boer; Hans P G Jansen; Sander J H van Deventer; Sotirios Tsimikas; Joseph L Witztum; John J P Kastelein; Dasja Pajkrt
Journal:  Viruses       Date:  2021-10-14       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.